Hydroxamic acid Mer / HDAC double-target inhibitor as well as preparation method and application thereof

By developing the Mer/HDAC dual-target inhibitor of hydroxamic acid, the problems of the existing HDAC inhibitors have been solved, and the side effects of existing HDAC inhibitors are greatly affected and the treatment effect on solid tumors is poor, thus achieving efficient inhibition of multiple tumors and showing that the patient has a relatively good effect on the patient. Good security and selectivity.

CN119059982AActive Publication Date: 2024-12-03HEBEI UNIV OF SCI & TECH
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202410964247.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-12-03
Estimated Expiration
2044-07-18

AI Technical Summary

Technical Problem

The existing HDAC inhibitors have major toxic side effects, poor therapeutic effect on solid tumors and drug resistance in clinical applications, and lack dual-target inhibitors for MerTK.

Method used

A dual-target inhibitor of hydroxamic acids was developed to achieve multi-target inhibition of Mer and HDAC1 through specific compound structures and synthesis routes, and is used to treat a variety of tumors, including chronic myelogen. Leukemia, non-small cell lung cancer and prostate cancer.

Benefits of technology

This compound showed good Mer and HDAC1 inhibitory activity, was broad-spectrum efficient for a variety of tumor cells, and had weak inhibitory effect on normal cells, had less potential cardiotoxicity, good safety and selectivity, suitable Used as an anti-tumor drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004951274990000021
    Figure BDA0004951274990000021
  • Figure BDA0004951274990000031
    Figure BDA0004951274990000031
  • Figure BDA0004951274990000041
    Figure BDA0004951274990000041
Patent Text Reader

Abstract

The invention relates to a hydroxamic acid Mer / HDAC double-target inhibitor, the hydroxamic acid Mer / HDAC double-target inhibitor has relatively strong inhibitory activity on Mer and HDAC, also shows specificity and selectivity on tumor cells and normal cells, and has low potential cardiotoxicity and relatively small toxic and side effects, and the invention also discloses application of the compound as an antitumor drug.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a hydroxamic acid Mer / HDAC dual-target inhibitor, a preparation method thereof and application of the compound in preventing and treating tumors and other related diseases by inhibiting the activities of Mer and HDAC1. Background Art

[0002] Mer receptor tyrosine kinase is a member of the TAM (Tyro3, ​​Axl, Mer) family and was first isolated from the chicken retrovirus RLP30. MerTK is widely present in normal human tissues and cells, such as testis, ovary, lung, liver tissue, peripheral blood leukocytes, macrophages, natural killer cells and platelets. Under normal physiological conditions, MerTK can mediate the second stage of platelet aggregation, macrophages and epithelial cells to clear and phagocytose apoptotic cells, regulate macrophage cytokine synthesis, and participate in a variety of complex physiological processes such as cell differentiation, survival, and migration. Abnormal activation or overexpression of MerTK is closely related to the development of many cancers, and poor prognosis is also related to MerTK. Acute lymphoblastic leukemia (ALL) is a common malignant tumor disease of the blood system and the most common malignant tumor in children. Studies have shown that MerTK is abnormally expressed in B-cell and T-cell ALL, but is not expressed at any stage in normal mice and human B-cells and T-cells. MerTK has been identified as a specific therapeutic target for ALL. Inhibiting Mer can reduce the survival of leukemia cells and make tumor cells more likely to die. At the same time, studies have also shown that MerTK is overexpressed in a variety of tumors such as non-small cell lung cancer, breast cancer, kidney cancer and pancreatic cancer. Therefore, inhibiting MerTK can effectively treat the occurrence and development of tumors.

[0003] At the same time, the occurrence of cancer is related to genomic changes and epigenetic modifications, such as DNA methylation and histone modification. Histone modification mainly includes histone acetylation, phosphorylation and methylation, among which histone acetylation is an important epigenetic modification in cancer.

[0004] Histone deacetylases (HDACs) are a class of enzymes that remove acetyl groups from histone ε-N-acetylysine and play an important role in gene regulation, transcription, cell proliferation, metastasis and angiogenesis. In the cell nucleus, histone acetylation and deacetylation are in a dynamic equilibrium, which is jointly regulated by histone acetyltransferases (HATs) and histone deacetylases. HATs transfer the acetyl group of acetyl-CoA to the lysine residue at the end of histones, making the structure of chromosomes loose, which is conducive to the specific binding of various transcription factors and co-transcription factors to DNA binding sites and activating gene transcription. HDACs deacetylate histones, and histones bind tightly to negatively charged DNA, hindering the binding of DNA polymerase to DNA and inhibiting gene transcription. Under pathological conditions, HDACs are overexpressed, causing dynamic imbalance, reducing the expression of certain anti-cancer genes and tumor suppressor genes, and ultimately leading to tumorigenesis.

[0005] According to the catalytic mechanism, location in the cell, homology with yeast sequences, and peptide chain folding, HDACs can be divided into two families and four categories: Class I: HDAC1, 2, 3, 8; Class II: HDAC4, 5, 6, 7, 9; Class III: SIRT1-7; Class IV: HDAC11. Among them, Class I, II, and IV belong to Zn 2+ The family of histone deacetylation catalyzed by the 2+ ; Class III belongs to the nicotinamide adenine dinucleotide-dependent family, and its catalytic histone deacetylation requires nicotinamide adenine dinucleotide.

[0006] HDAC inhibitors inhibit the activity of HDAC, enhance the acetylation of histones, promote the binding of transcription factors to DNA chains, and activate the expression of specific genes such as tumor suppressor genes, thereby inhibiting the proliferation of tumor cells and promoting tumor cell apoptosis. The structure of HDAC inhibitors is generally composed of Cap group, Linker and Zn 2+ The Cap group is generally a hydrophobic and aromatic group that can interact with the surface recognition area of ​​the HDAC active pocket; ZBG interacts with the Zn at the bottom of the HDAC active pocket. 2+Chelation forms a complex, which is the key pharmacophore; Linker is composed of a linear or cyclic hydrophobic structure connecting the Cap group and ZBG. Currently, there are 5 HDAC inhibitors on the market, of which Vorinostat, Romidepsin, Belinostat, and Panobinostat are approved by the US FDA for the treatment of cutaneous T-cell lymphoma, multiple myeloma, and peripheral T-cell lymphoma. Chidamide is approved in China for the treatment of relapsed or refractory peripheral T-cell lymphoma.

[0007]

[0008] HDAC inhibitors still have the following shortcomings: (1) they have significant clinical toxic side effects, such as nausea, vomiting, and bone marrow suppression; (2) they are only effective in treating hematological tumors, but not in treating solid tumors; and (3) they are prone to drug resistance during use.

[0009] Clinical studies have shown that some new multi-target inhibitors are significantly more effective than single-target inhibitors. By inhibiting tumors through multiple channels, we can overcome the drug resistance of single targets and avoid the toxic side effects caused by combined medication. Currently, some HDAC-based dual-target inhibitors have been reported, such as PI3K / HDAC inhibitors, c-Met / HDAC inhibitors, EGFR / HDAC inhibitors, etc. There are no literature reports on Mer and HDAC dual-target inhibitors. Summary of the invention

[0010] The purpose of the present invention is to provide a hydroxamic acid Mer / HDAC dual-target inhibitor and its application in the preparation of anti-tumor drugs, so as to discover Mer / HDAC dual-target inhibitors with new structural types to meet the needs of clinical application.

[0011] The present invention adopts the following technical solution:

[0012] A hydroxamic acid Mer / HDAC dual-target inhibitor, the general formula is:

[0013]

[0014] R 1 Selected from alkyl, alkoxyethyl, cycloalkyl, substituted cycloalkyl;

[0015] R 2 Selected from H, aryl, aromatic heterocyclic group, substituted aromatic heterocyclic group.

[0016] Furthermore, R 1 is selected from trans-hydroxycyclohexyl, cyclohexyl, methoxyethyl, trans-methylcyclohexyl; R 2 Selected from H, phenyl, 5-pyrimidinyl, 3-methoxy-2-pyridinyl.

[0017] Furthermore, R 1 Selected from the following groups: R 2 The groups are: H,

[0018] Specifically, the following specific compounds are preferred from the compounds of formula (I):

[0019] I-1:N 1 -Hydroxy-N 8 -(4-((4-(((trans)-4-hydroxycyclohexyl)amino)-[5,5'-dipyrimidinyl]-2-yl)amino)phenyl)octanediamide;

[0020] I-2: N 1 -Hydroxy-N 8 -(4-((4-(((trans)-4-hydroxycyclohexyl)amino)-5-phenylpyrimidin-2-yl)amino)phenyl)octanediamide;

[0021] I-3:N 1 -Hydroxy-N 8 -(4-((4-(((trans)-4-hydroxycyclohexyl)amino)-5-(6-methoxypyridin-2-yl)pyrimidin-2-yl)amino)phenyl)octanediamide;

[0022] I-4: N 1 -Hydroxy-N 8 -(4-((4-(((trans)-4-hydroxycyclohexyl)amino)pyrimidin-2-yl)amino)phenyl)octanediamide;

[0023] I-5: N 1 -Hydroxy-N 8 -(4-((4-(((trans)-4-methylcyclohexyl)amino)pyrimidin-2-yl)amino)phenyl)octanediamide;

[0024] I-6: N 1 -(4-((4-(cyclohexylamino)pyrimidin-2-yl)amino)phenyl)-N 8 -Hydroxyoctanamide;

[0025] I-7: N 1 -Hydroxy-N 8 -(4-((4-(((trans)-2-hydroxycyclohexyl)amino)pyrimidin-2-yl)amino)phenyl)octanediamide;

[0026] I-8: N 1 -Hydroxy-N 8-(4-((4-((2-methoxyethyl)amino)pyrimidin-2-yl)amino)phenyl)subanediamide.

[0027] The structural formulas of the above compounds are shown in Table 1.

[0028] Table 1 Preferred compound numbers and corresponding structural formulas

[0029]

[0030] A method for preparing the above hydroxamic acid Mer / HDAC dual-target inhibitor,

[0031] (1) Synthesis routes of target compounds I-1 to I-3

[0032]

[0033] The specific steps include:

[0034] 1) 2,4-dichloro-5-bromopyrimidine reacts with compound II in the presence of an acid-binding agent to obtain intermediate III;

[0035] 2) Intermediate III reacts with 8-((4-aminophenyl)amino)-8-oxooctanoic acid methyl ester in the presence of an acid catalyst to obtain intermediate IV;

[0036] 3) Intermediate IV and compound V are subjected to Suzuki coupling reaction in the presence of a catalyst to obtain intermediate VI;

[0037] 4) intermediate VI is subjected to hydrolysis reaction in the presence of a base catalyst to obtain intermediate VII;

[0038] 5) intermediate VII is reacted with O-(tetrahydro-2H-pyran-2-yl)hydroxylamine in the presence of a base catalyst to obtain intermediate VIII;

[0039] 6) Intermediate VIII is deprotected to obtain target compounds I-1 to I-3.

[0040] (2) Synthesis routes of target compounds I-4 to I-8

[0041]

[0042] The specific steps include:

[0043] a) 2,4-dichloropyrimidine reacts with compound II in the presence of an acid-binding agent to obtain intermediate IX;

[0044] b) reacting methyl 8-((4-aminophenyl)amino)-8-oxooctanoate with intermediate IX in the presence of an acid catalyst to obtain intermediate X through nucleophilic substitution reaction;

[0045] c) intermediate X is subjected to a hydrolysis reaction in the presence of a base catalyst to obtain intermediate XI;

[0046] d) intermediate XI is reacted with O-(tetrahydro-2H-pyran-2-yl)hydroxylamine in the presence of a base catalyst to obtain intermediate XII;

[0047] e) Intermediate XII is deprotected to obtain target compounds I-4 to I-8.

[0048] In the above preparation method, in steps 1) and a), the acid-binding agent is a commonly used organic base, such as triethylamine, DIPEA, etc.; and the reaction temperature is 10-40°C.

[0049] In the above preparation method, in steps 2) and b), the acid is a commonly used organic acid, such as p-toluenesulfonic acid, benzenesulfonic acid, methanesulfonic acid, etc.; the reaction temperature is 60-100°C.

[0050] In the above preparation method, in step 3), the catalyst is a commonly used palladium catalyst, such as Pd(PPh3)2Cl2, Pd(PPh3)4, Pd(dppf)2Cl2, etc.; the reaction temperature is 60-100°C.

[0051] In the above preparation method, in steps 4) and c), the base is a commonly used inorganic base, such as lithium hydroxide, sodium hydroxide, potassium hydroxide, etc.; and the reaction temperature is 10-40°C.

[0052] In the above preparation method, in steps 5) and d), the condensing agent is HBTU, HATU, HOBt or TFCH; the base catalyst is triethylamine, N,N-diisopropylethylamine or pyridine; the reaction solvent is DMF or DMA; and the reaction temperature is 10 to 40°C.

[0053] In the above preparation method, in steps 6) and e), the catalyst is trifluoroacetic acid, hydrochloric acid or sulfuric acid; the reaction solvent is acetonitrile / water, tetrahydrofuran / water, 1,4-dioxane / water; and the reaction temperature is 10-40°C.

[0054] A use of the above hydroxamic acid Mer / HDAC dual-target inhibitor in the preparation of anti-tumor drugs.

[0055] In the application, the Mer / HDAC dual-target inhibitor is specifically a Mer / HDAC1 dual-target inhibitor.

[0056] In the application, the indications of the anti-tumor drug include one or more of chronic myeloid leukemia, myelomonocytic leukemia, non-small cell lung cancer, colorectal cancer, liver cancer and prostate cancer.

[0057] The compounds of the present invention can be used in combination for mammals (including humans) that need tumor treatment by oral administration, injection, etc., wherein oral administration is the best, and the dosage is 0.0001 mg / kg to 200 mg / kg body weight per day. The best dosage depends on the individual, usually starting with a small dosage and then gradually increasing the dosage.

[0058] The anti-tumor drug comprises a therapeutically effective dose of the compound represented by formula (I) and a pharmaceutically acceptable carrier.

[0059] The carrier refers to a common carrier in the pharmaceutical field, for example: a diluent, an excipient such as water, etc.; a binder such as cellulose derivatives, gelatin, polyvinyl pyrrolidone, etc.; a filler such as starch, etc.; a disintegrant such as calcium carbonate, sodium bicarbonate; in addition, other auxiliary agents such as flavoring agents and sweeteners may also be added to the composition.

[0060] The anti-tumor pharmaceutical composition of the present invention can be prepared into conventional solid preparations, such as tablets, capsules, etc., for oral administration, or can be prepared into injections for injection. Various dosage forms can be prepared by conventional methods in the pharmaceutical field, wherein the content of active ingredient I is 0.1% to 99.5% (by weight) of the weight of the compound.

[0061] The beneficial effects of the present invention are:

[0062] 1) The compounds of the present invention have novel structures, good Mer and HDAC1 inhibitory activities, and good inhibitory effects on a variety of human tumor cells, with broad-spectrum and high-efficiency characteristics. They may also have good therapeutic effects on diseases caused by abnormal gene expression, such as endocrine disorders, immune system diseases, genetic diseases and nervous system diseases.

[0063] 2) The compounds of the present invention have a weak inhibitory effect on normal cells while effectively inhibiting tumor cells, showing good selective inhibitory activity and having a good prospect for clinical application in tumors.

[0064] 3) The compounds of the present invention have weak inhibitory effects on hERG potassium channels, have low potential cardiac toxicity, have good safety, and are worth further study.

[0065] In summary, the novel structural type compounds of the present invention not only have strong enzyme inhibitory activity, but also show specificity and selectivity for tumor cells and normal cells. At the same time, the novel structural compounds are more safe, have less toxic side effects, and are easier to use as anti-tumor drugs. DETAILED DESCRIPTION

[0066] The present invention is further described in detail below with reference to examples, but the embodiments of the present invention are not limited thereto.

[0067] Example 1 Synthesis of the intermediate trans-4-((5-bromo-2-chloropyrimidin-4-yl)amino)cyclohexanol

[0068]

[0069] Dissolve 2,4-dichloro-5-bromopyrimidine (5.00 g, 17.99 mmol), trans-4-aminocyclohexane-1-ol (2.90 g, 25.19 mmol), and triethylamine (2.73 g, 26.99 mmol) in isopropanol (i-PrOH, 170 mL) and stir at room temperature for 6 h. After the reaction, the reaction solution was concentrated to remove the solvent, slurried with petroleum ether for 1 h, filtered, and the filter cake was washed with water and dried to obtain 5.66 g of a white solid with a yield of 99.1%. HRMS: m / z C 10 H 14 BrClN3O[M+H] + 305.9931, Found 305.9827.

[0070] Example 2 Synthesis of Intermediate 8-((4-((5-bromo-4-(((trans)-4-hydroxycyclohexyl)amino)pyrimidin-2-yl)amino)phenyl)amino)-8-oxooctanoic acid methyl ester

[0071]

[0072] 8-((4-aminophenyl)amino)-8-oxooctanoic acid methyl ester (2.0g, 7.19mmol), intermediate trans-4-((5-bromo-2-chloropyrimidin-4-yl)amino)cyclohexanol (2.63g, 8.63mmol), PTSA (1.86g, 10.79mmol) were dissolved in N,N-dimethylformamide (DMF, 20mL), heated to 90°C, and reacted for 3h. After the reaction, the reaction solution was naturally cooled to room temperature, slowly dripped into 200mL of ice water, and adjusted to pH 9.0 with 2N Na2CO3 aqueous solution. Solid precipitated, filtered, and the filter cake was dried. The filter cake was purified by column chromatography (DCM:MeOH=80:1~20:1) to obtain 2.12g of white solid with a yield of 53.9%. HRMS:m / zC 25 H 35 BrN5O4[M+H] + 548.1794,Found 548.1812.

[0073] Example 3 Synthesis of Intermediate 8-((4-((4-(((trans)-4-hydroxycyclohexyl)amino)-[5,5'-dipyrimidinyl]-2-yl)amino)phenyl)amino)-8-oxooctanoic acid methyl ester

[0074]

[0075] The intermediate 8-((4-((5-bromo-4-(((trans)-4-hydroxycyclohexyl)amino)pyrimidin-2-yl)amino)phenyl)amino)-8-oxooctanoic acid methyl ester (1.00 g, 1.82 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (1.51 g, 7.32 mmol), NaI (82.18 mg, 0.54 mmol), 2N Na2CO3 solution (10 mL) were dissolved in DMF (15 mL), N2 was protected, and after 10 min, Pd(PPh3)2Cl2 (0.64 g, 0.92 mmol) was added, the temperature was raised to 90°C, and the reaction was carried out for 2 h. After the reaction was completed, the reaction solution was naturally cooled to room temperature, filtered through diatomaceous earth, concentrated, solid precipitated, filtered, and the filter cake was dried. The filter cake was purified by column chromatography (DCM:MeOH=80:1-20:1) to obtain 513.0 mg of a yellow solid with a yield of 50.4%. HRMS: m / zC 29 H 38 N7O4[M+H] + 548.2907,Found 548.2929.

[0076] Example 4 Synthesis of Intermediate 8-((4-((4-(((trans)-4-hydroxycyclohexyl)amino)-[5,5'-dipyrimidinyl]-2-yl)amino)phenyl)amino)-8-oxooctanoic acid

[0077]

[0078] The intermediate 8-((4-((4-(((trans)-4-hydroxycyclohexyl)amino)-[5,5'-dipyrimidine]-2-yl)amino)phenyl)amino)-8-oxooctanoic acid methyl ester (513.0 mg, 0.93 mmol) was dissolved in CH3OH (16 mL) / THF (16 mL), and 1M aq LiOH (8 mL) was added and stirred at room temperature for 3 h. After the reaction, the reaction solution was concentrated and slowly dripped into 40 mL of ice water, and the pH was adjusted to about 3.0 with 2M HCl aqueous solution. Solid precipitated, filtered, and the filter cake was dried to obtain 447.2 mg of white solid with a yield of 90.1%. HRMS: m / z C 28 H 36 N7O4[M+H] + 534.2751,Found 534.2782.

[0079] Example 5 Intermediate N 1-(4-((4-(((trans)-4-hydroxycyclohexyl)amino)-[5,5'-bipyrimidinyl]-2-yl)amino)phenyl)-N 8 Synthesis of -((tetrahydro-2H-pyran-2-yl)oxy)octanediamide

[0080]

[0081] The intermediate 8-((4-((4-(((trans)-4-hydroxycyclohexyl)amino)-[5,5'-dipyrimidine]-2-yl)amino)phenyl)amino)-8-oxooctanoic acid (180.00 mg, 0.34 mmol), O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (43.47 mg, 0.37 mmol), HATU (154.01 mg, 0.41 mmol), triethylamine (170.78 mg, 1.69 mmol) were dissolved in DMF (6 mL), N2 protected, and stirred at room temperature for 7 h. After the reaction, the reaction solution was concentrated and slowly dripped into 30 mL of ice water. Solid precipitated, filtered, and the filter cake was dried. The filter cake was purified by P-TLC (DCM:MeOH=10:1) to obtain 71.4 mg of white solid with a yield of 33.5%. HRMS: m / z C 33 H 45 N8O5[M+H] + 633.3435,Found 633.3473.

[0082] Example 6N 1 -Hydroxy-N 8 Synthesis of -(4-((4-(((trans)-4-hydroxycyclohexyl)amino)-[5,5'-bipyrimidinyl]-2-yl)amino)phenyl)octanediamide (target compound I-1)

[0083]

[0084] The intermediate N 1 -(4-((4-(((trans)-4-hydroxycyclohexyl)amino)-[5,5'-bipyrimidinyl]-2-yl)amino)phenyl)-N 8 -((Tetrahydro-2H-pyran-2-yl)oxy)octanediamide (71.4 mg, 0.11 mmol) was dissolved in MeCN (24 mL) / H2O (6 mL), TFA (1 mL) was added, and the reaction was stirred at room temperature for 6 h. After the reaction, the reaction solution was concentrated and slowly dripped into 30 mL of ice water, and the pH was adjusted to about 9.0 with 2N Na2CO3 aqueous solution. Solid precipitated, filtered, and the filter cake was dried to obtain 58.5 mg of light yellow solid, with a yield of 94.5%. HRMS: m / z C 28 H 37N8O4[M+H] + 549.2860,Found 549.2928.

[0085] 1 H NMR (500MHz, DMSO-d6) δ10.35(s,1H),9.76(s,1H),9.19(s,1H),9.13(s,1H),8.77(s,2H),7.79(s,1H),7.72(d,J=8.5Hz,2H),7.48(d,J=8.5Hz, 2H),6.65(d,J=6.4Hz,1H),4.64(s,1H),3.94(s,1H),3.39(s,1H),2.26 (s,2H),1.98-1.84(m,6H),1.57(s,2H),1.49(s,2H),1.35-1.24(m,8H).

[0086] Example 7N 1 -Hydroxy-N 8 Synthesis of -(4-((4-(((trans)-4-hydroxycyclohexyl)amino)-5-phenylpyrimidin-2-yl)amino)phenyl)octanediamide (target compound I-2)

[0087]

[0088] According to the preparation method of the target compound I-1 in Examples 1 to 6, the target compound I-2 can be prepared with a yield of 18.6%. HRMS: m / z C 30 H 39 N6O4[M+H] + 547.2955,Found 547.3027.

[0089] 1H NMR(500MHz,DMSO-d6)δ10.35(s,1H),9.75(d,J=3.6Hz,1H),9.07(s,1H),8.66(s,1H),7.75-7.7 0(m,3H),7.49-7.43(m,4H),7.38(d,J=7.3Hz,2H),7.35(t,J=7.2Hz,1H),5.83(d,J=7.5Hz,1H),4 .62(s,1H),3.94(s,1H),3.40(s,1H),2.26(t,J=7.2Hz,2H),1.97-1.90(m,4H),1.86(d,J=10.0Hz ,2H),1.57(t,J=4.1Hz,2H),1.50(t,J=6.4Hz,2H),1.34(d,J=12.8Hz,2H),1.30(d,J=9.0Hz,6H).

[0090] Example 8N 1 -Hydroxy-N 8 Synthesis of -(4-((4-(((trans)-4-hydroxycyclohexyl)amino)-5-(6-methoxypyridin-2-yl)pyrimidin-2-yl)amino)phenyl)octanediamide (target compound I-3)

[0091]

[0092] According to the preparation method of the target compound I-1 in Examples 1 to 6, the target compound I-3 can be prepared with a yield of 55.7%. HRMS: m / z C 30 H 40 N7O5[M+H] + 578.3013, Found 578.3103.

[0093] 1 H NMR(500MHz,DMSO-d6)δ10.35(s,1H),10.20(s,1H),9.89(s,2H),8.58(s,1H),7.82 (s,1H),7.65(d,J=7.6Hz,2H),7.59(d,J=7.0Hz,2H),7.55(d,J=6.7Hz,1H),6.80(d ,J=7.4Hz,1H),4.70(s,1H),3.93(s,4H),3.62(s,1H),2.29(s,2H),2.09(d,J=7.7H z, 2H), 1.94 (s, 4H), 1.58 (s, 2H), 1.50 (s, 2H), 1.39 (d, J = 11.4Hz, 2H), 1.29 (s, 6H).

[0094] Example 9 Synthesis of Intermediate (trans)-4-((2-chloropyrimidin-4-yl)amino)cyclohexane-1-ol)

[0095]

[0096] According to the preparation method of the intermediate (trans)-4-((5-bromo-2-chloropyrimidin-4-yl)amino)cyclohexanol in Example 1, the intermediate (trans)-4-((2-chloropyrimidin-4-yl)amino)cyclohexane-1-ol) can be prepared with a yield of 70.8%. HRMS: m / z C 10 H 15 ClN3O[M+H] + 228.0825, Found 228.0831.

[0097] Example 10 Synthesis of Intermediate 8-((4-((4-(((trans)-4-hydroxycyclohexyl)amino)pyrimidin-2-yl)amino)phenyl)amino)-8-oxooctanoic acid methyl ester

[0098]

[0099] According to the preparation method of the intermediate 8-((4-((5-bromo-4-(((trans)-4-hydroxycyclohexyl)amino)pyrimidin-2-yl)amino)phenyl)amino)-8-oxooctanoic acid methyl ester in Example 2, the intermediate 8-((4-((4-(((trans)-4-hydroxycyclohexyl)amino)pyrimidin-2-yl)amino)phenyl)amino)-8-oxooctanoic acid methyl ester can be prepared with a yield of 30.9%. HRMS: m / z C 25 H 36 N5O4[M+H] + 470.2689,Found 470.2700.

[0100] Example 11 Synthesis of Intermediate 8-((4-((4-(((trans)-4-hydroxycyclohexyl)amino)pyrimidin-2-yl)amino)phenyl)amino)-8-oxooctanoic acid

[0101]

[0102] According to the preparation method of the intermediate 8-((4-((4-(((trans)-4-hydroxycyclohexyl)amino)-[5,5'-dipyrimidin]-2-yl)amino)phenyl)amino)-8-oxooctanoic acid in Example 4, the intermediate 8-((4-((4-(((trans)-4-hydroxycyclohexyl)amino)pyrimidin-2-yl)amino)phenyl)amino)-8-oxooctanoic acid can be prepared with a yield of 95.9%. HRMS: m / z C 24 H 34N5O4[M+H] + 456.2533,Found 456.2551.

[0103] Example 12 Intermediate N 1 Synthesis of -(4-((4-(((trans)-4-hydroxycyclohexyl)amino)pyrimidin-2-yl)amino)phenyl)-N8-((tetrahydro-2H-pyran-2-yl)oxy)octanediamide

[0104]

[0105] According to Example 5, intermediate N 1 -(4-((4-(((trans)-4-hydroxycyclohexyl)amino)-[5,5'-bipyrimidinyl]-2-yl)amino)phenyl)-N 8 -((tetrahydro-2H-pyran-2-yl)oxy)octanediamide preparation method, can prepare intermediate N 1 -(4-((4-(((trans)-4-hydroxycyclohexyl)amino)pyrimidin-2-yl)amino)phenyl)-N 8 -((tetrahydro-2H-pyran-2-yl)oxy)octanediamide, yield 39.1%. HRMS: m / z C 29 H 43 N6O5[M+H] + 555.3217,Found 555.3265.

[0106] Example 13N 1 -Hydroxy-N 8 Synthesis of -(4-((4-(((trans)-4-hydroxycyclohexyl)amino)pyrimidin-2-yl)amino)phenyl)octanediamide (target compound I-4)

[0107]

[0108] According to the preparation method of the target compound I-1 in Example 6, the target compound I-4 can be prepared with a yield of 29.6%. HRMS: m / z C 24 H 35 N6O4[M+H] + 471.2642,Found 471.2716.

[0109] 1H NMR(500MHz,DMSO-d6)δ10.34(s,1H),9.68(s,1H),8.83(s,1H),8.66(s,1H ),7.74(s,1H),7.68(d,J=7.3Hz,2H),7.43(d,J=7.8Hz,2H),7.01(s,1H),5 .86(s,1H),4.61(s,1H),3.74(s,1H),3.43(s,1H),2.25(s,2H),1.95(s,2H ), 1.88 (d, J = 9.9Hz, 2H), 1.57 (s, 2H), 1.49 (s, 2H), 1.25 (d, J = 11.5Hz, 10H).

[0110] Example 14N 1 -Hydroxy-N 8 Synthesis of -(4-((4-(((trans)-4-methylcyclohexyl)amino)pyrimidin-2-yl)amino)phenyl)octanediamide (target compound I-5)

[0111]

[0112] According to the preparation method of target compound I-4 in Examples 9 to 13, target compound I-5 can be prepared with a yield of 48.8%. HRMS: m / z C 25 H 37 N6O3[M+H] + 469.2849,Found 469.2921.

[0113] 1 H NMR(500MHz,DMSO-d6)δ10.35(s,1H),10.12(s,1H),9.89(s,1H),8.67(s,1H),8.51(s,1H),7.7 4(d,J=4.7Hz,1H),7.58(d,J=8.6Hz,2H),7.53(d,J=8.2Hz,2H),6.09(d,J=5.8Hz,1H),3.73(s,1 H),2.29(t,J=7.3Hz,2H),2.04-1.89(m,4H),1.58(d,J=12.2Hz,2H),1.49(t,J=6.4Hz,2H),2.29 (t,J=6.8Hz,2H),1.38(s,1H),1.32-1.23(m,6H),1.00(q,J=11.7Hz,2H),0.91(d,J=6.4Hz,3H).

[0114] Example 15N 1-(4-((4-(cyclohexylamino)pyrimidin-2-yl)amino)phenyl)-N 8 Synthesis of -hydroxyoctanamide (target compound I-6)

[0115]

[0116] According to the preparation method of target compound I-4 in Examples 9 to 13, target compound I-6 can be prepared with a yield of 67.9%. HRMS: m / z C 24 H 35 N6O3[M+H] + 455.2692,Found 455.2754.

[0117] 1 H NMR (500MHz, DMSO-d6) δ10.35(s,1H),10.07(s,1H),9.87(s,1H),8.67(s,1H),8.45(s,1H),7.74(s,1H),7.55(d,J=9.6H z, 4H), 6.10 (s, 1H), 3.79 (s, 1H), 2.28 (s, 2H), 1.99-1.90 (m, 4H), 1.76 (d, J = 9.3Hz, 2H), 1.66-1.45 (m, 6H), 1.28 (s, 8H).

[0118] Example 16N 1 -Hydroxy-N 8 Synthesis of -(4-((4-(((trans)-2-hydroxycyclohexyl)amino)pyrimidin-2-yl)amino)phenyl)octanediamide (target compound I-7)

[0119]

[0120] According to the preparation method of target compound I-4 in Examples 9 to 13, target compound I-7 can be prepared with a yield of 25.7%. HRMS: m / z C 24 H 35 N6O4[M+H] + 471.2642,Found 471.2704.

[0121] 1H NMR (500MHz, DMSO-d6) δ10.35(s,1H),9.67(s,1H),8.80(s,1H),8.71(s,1H),7.74(s,1H),7.68(d,J=7.6Hz,2H),7.43(d,J=7.5Hz,2H),6.99(s ,1H),5.92(s,1H),4.63(s,1H),3.69(s,1H),3.50(s,1H),2.25(s,2H), 2.09-1.90(m,4H),1.67(s,2H),1.57(s,2H),1.49(s,2H),1.27(s,8H).

[0122] Example 17N 1 -Hydroxy-N 8 Synthesis of -(4-((4-((2-methoxyethyl)amino)pyrimidin-2-yl)amino)phenyl)octanediamide (target compound I-8)

[0123]

[0124] According to the preparation method of the target compound I-4 in Examples 9 to 13, the target compound I-8 can be prepared with a yield of 48.7%. HRMS: m / z C 21 H 31 N6O4[M+H] + 431.2329,Found 431.2415.

[0125] 1 H NMR (400MHz, DMSO-d6) δ10.32(s,1H),9.64(s,1H),8.81(s,1H),8.67(s,1H),7.77(s,1H),7.65(d,J=7.0Hz,2H),7.42(d,J=7 .2Hz,2H),7.15(s,1H),5.93(s,1H),3.48(s,3H),3.28(s,2H),2.25(s,2H),1.94(s,2H),1.53(d,J=28.6Hz,4H),1.28(s,4H).

[0126] Example 18 In vitro inhibitory activity test of the compounds of the present invention on Mer and HDAC1

[0127] (I) Select a kit to test the inhibitory activity of the compound on Mer, and perform the test according to the instructions of the kit. 50 Test, the test operation is as follows:

[0128] (1) Experimental process

[0129] 1. Prepare 1× buffer: HEPES 50mM, MgCl2 10mM, EGTA 1mM, NP-40 0.0001%, DTT 2mM.

[0130] 2. Make compound dilutions with DMSO. For the test compound, make a 100× final concentration solution.

[0131] 3. Use an automated liquid handler to transfer 100 nL of compound to a 384-well plate. The final DMSO% in the experiment was 1%.

[0132] 4. Dilute the enzyme stock solution to a concentration of 0.5 nM with 1× assay buffer to make a 2× working solution. Manually add 5 μL to the assay plate using a multichannel pipette (final 0.25 nM), spin at 1000 rpm, centrifuge for 30 seconds, and incubate at 25°C for 30 minutes.

[0133] 5. Dilute the substrate solution with 1× assay buffer. Manually add 5 μL of the mixture or buffer (ATP final 30 uM and TK-Sub-Biotin final 2 uM) using a multichannel pipette, add to the test plate, spin at 1000 rpm, and centrifuge for 30 seconds.

[0134] 6. After 60 min at 30°C, add 10 μL of detection solution to each detection well.

[0135] 7. Mix briefly in a centrifuge and equilibrate for 60 minutes.

[0136] 8. Record the luminescence conditions.

[0137] (2) Data Analysis

[0138]

[0139] Conversion%-sample: conversion% value of sample;

[0140] Conversion%-min: average conversion% value of negative control;

[0141] Conversion%-max: average conversion rate% value of positive control;

[0142] Conversion%-maxDose-response curves with PraphPadPrism5 and IC 50 Perform fitting;

[0143] log(inhibitor)vs.response-Variable slope program, the calculation formula is as follows:

[0144] Y=Bottom+(Top-Bottom) / (1+10^((LogIC 50 -X)*HillSlope))

[0145] The test results are shown in Table 2.

[0146] (II) Use a kit to test the inhibitory activity of the compound on HDAC1, and refer to the instructions of the kit for the test procedure. 50 Test, the test operation is as follows:

[0147] (1) Compound preparation

[0148] The compound was prepared into a DMSO solution with a stock concentration of 10 mM and stored in the dark for future use.

[0149] (2) HDAC1 reaction process

[0150] a. Prepare 1× reaction solution.

[0151] b. Compound preparation: The final concentration of the compound test is 10uM, 3-fold dilution, 8 concentrations, and single-well detection. The final concentration of the positive control compound Vorinostat is 3μM, 3-fold dilution, 10 concentrations, and multiple-well detection. Gradually dilute to the corresponding 100-fold final concentration solution in the 384-well Source plate, and then use Echo550 to transfer 250nL to the 384-well reaction plate for testing. Transfer 250nL of 100% DMSO to both the Max well and the Min well.

[0152] c. Use 1× reaction solution to prepare 1.67× enzyme solution.

[0153] d. Add 15 μL of 1.67× enzyme solution to each well and 15 μL of 1.6× reaction solution to the Min well. Incubate at room temperature for 15 minutes.

[0154] e. Use 1× reaction solution to prepare 2.5× substrate mixed solution.

[0155] f. Add 10 μL of 2.5× substrate mixed solution to each well of the reaction plate to start the reaction.

[0156] g. Use Synergy to continuously read the fluorescence signal.

[0157] (3) Data analysis

[0158] The linear response segment was selected to obtain the slope and the percentage inhibition rate was calculated using the following formula:

[0159]

[0160] Where: Mean(Max) is the mean of the slope values ​​of the Max wells (containing DMSO and enzyme); Mean(Min) is the mean of the slope values ​​of the Min wells (wells without enzyme); Sample Signal is the slope value of the compound well.

[0161] Fitting the dose-effect curve: The log value of the compound concentration is used as the X-axis, and the corresponding percentage inhibition rate is used as the Y-axis. The log (inhibitor) vs. response-Variable slope of the analysis software GraphPad Prism 5 is used to fit the dose-effect curve, so as to obtain the IC value of each compound for inhibiting enzyme activity. 50 The test results are shown in Table 2.

[0162] Table 2 Inhibitory activity results of compounds on Mer and HDAC1 (IC 50 / nM)

[0163]

[0164] As can be seen from Table 2 above, the compounds of the present invention have good inhibitory activity against Mer and HDAC1, and the results are all at the nanomolar level. Among them, I-4 has the best activity and has good inhibitory activity against both targets. The IC 50 The value is 164.2nM, and the IC value for HDAC1 50 The value is 54.8nM.

[0165] Example 19 Tumor cell inhibition activity test of the compounds of the present invention

[0166] The activity of the tested compounds against human chronic myeloid leukemia cells K562, human hepatoma cell line HepG2, human colorectal cancer cell line HCT116, non-small cell lung cancer A549, human prostate cancer cell line PC-3 and human myelomonocytic leukemia cells MV4-11 was analyzed. 50 The value was measured by CCK-8 method, and the test operation was as follows:

[0167] (1) Cell inoculation: Take cells in the logarithmic growth phase and inoculate them into a 96-well plate, with 10,000 cells per well. Culture for 12 hours to allow the cells to adhere normally.

[0168] (2) Drug preparation: Weigh the drug and dissolve it in the corresponding solvent to prepare a stock solution with a concentration of 1 mM. Perform a 2-fold gradient dilution in complete culture medium during the test.

[0169] (3) Drug treatment: The culture medium in the 96-well plate was aspirated and the cells were washed once with PBS. 100 μL of culture medium containing different drug concentrations was added to the wells, and 3 replicate wells were set for each measurement; at the same time, DMSO control wells and blank culture medium control wells were set. The drug was allowed to act for 12 hours.

[0170] (4) CCK8 detection: 10 μL CCK8 was added to each well, and the cells were cultured for 1-2 hours. The detection wavelength was 450 nm and the reference wavelength was 600-650 nm.

[0171] (5) Result statistics: Cell survival rate = [(As-Ab) / (Ac-Ab)] × 100%

[0172] Wherein: As: absorbance of the experimental well (culture medium containing cells, CCK8, and the drug to be tested); Ab: absorbance of the blank well (culture medium without cells and the drug to be tested, CCK8); Ac: absorbance of the control well (culture medium containing cells, CCK8, and no drug to be tested).

[0173] (6) Graphpad Prism 9.5.1 software was used to calculate the IC for the above three different cell types. 50 The test results are shown in Table 3 (unit: μM).

[0174] Table 3 In vitro inhibitory activity of compounds on tumor cells (IC 50 / μM)

[0175]

[0176] As can be seen from Table 3, the present invention has good inhibitory effects on the above six types of tumor cells, among which the anti-proliferation activity IC 50 The value is 3.4~10.5μM; the antiproliferative activity IC of HepG2 cells 50 The value is 2.6~12.4μM; IC value of antiproliferative activity against HCT116 cells 50 The value is 2.2~11.3μM; IC value of antiproliferative activity against MV4-11 cells 50 The value is 2.8~13.2μM; the IC value of antiproliferative activity on PC-3 cells 50 The value is 2.7~12.5μM; the antiproliferative activity IC of A549 cells 50 The values ​​are 3.3~14.6μM.

[0177] Example 20 In vitro inhibitory activity test of the compounds of the present invention on normal cells

[0178] The activity of the compounds of the present invention on MRC-5 human embryonic lung fibroblasts was determined, and the IC50 The value was measured by CCK-8 method, and the test operation was as follows:

[0179] (1) Cell inoculation: Take cells in the logarithmic growth phase and inoculate them into a 96-well plate, with 10,000 cells per well. Culture for 12 hours to allow the cells to adhere normally.

[0180] (2) Drug preparation: Weigh the drug and dissolve it in the corresponding solvent to prepare a stock solution with a concentration of 1 mM. Perform a 2-fold gradient dilution in complete culture medium during the test.

[0181] (3) Drug treatment: The culture medium in the 96-well plate was aspirated and the cells were washed once with PBS. 100 μL of culture medium containing different drug concentrations was added to the wells, and 3 replicate wells were set for each measurement; at the same time, DMSO control wells and blank culture medium control wells were set. The drug was allowed to act for 12 hours.

[0182] (4) CCK8 detection: 10 μL CCK8 was added to each well, and the cells were cultured for 1-2 hours. The detection wavelength was 450 nm and the reference wavelength was 600-650 nm.

[0183] (5) Result statistics: Cell survival rate = [(As-Ab) / (Ac-Ab)] × 100%

[0184] Wherein: As: absorbance of the experimental well (culture medium containing cells, CCK8, and the drug to be tested); Ab: absorbance of the blank well (culture medium without cells and the drug to be tested, CCK8); Ac: absorbance of the control well (culture medium containing cells, CCK8, and no drug to be tested).

[0185] (6) Graphpad Prism 9.5.1 software was used to calculate the IC values ​​of different drugs on MRC-5 human embryonic lung fibroblasts 50 The test results are shown in Table 4 (unit: μM).

[0186] Table 4 In vitro inhibitory activity of compounds on normal cells

[0187]

[0188] As can be seen from Table 4 above, the IC values ​​of the compounds of the present invention for normal cells MRC-5 are 50 The value is 20.4-34.1 μM, and the inhibitory effect is weak, indicating that the compound of the present invention has good selectivity and less toxic and side effects on normal cells.

[0189] Example 21 hERG potassium channel effect test of the compounds of the present invention

[0190] The hERG potassium channel inhibition test was used to preliminarily investigate the potential cardiac toxicity and side effects of the compounds of the present invention in vitro. The test procedure is as follows:

[0191] (1) Cell preparation: CHO-hERG cells were cultured at 175 cm 2 In the culture flask, when the cell density grows to 60-80%, remove the culture medium, wash once with 7mL PBS (Phosphate Buffered Saline), and then add 3mL Detachin for digestion. After digestion is complete, add 7mL culture medium for neutralization, then centrifuge, aspirate the supernatant, and add 5mL culture medium for resuspending to ensure that the cell density is 2-5×10 6 / mL.

[0192] (2) Electrophysiological recording process: The single-cell high-impedance sealing and whole-cell pattern formation process were all automatically completed by the Qpatch instrument. After obtaining the whole-cell recording mode, the cell was clamped at -80 mV. Before a 5-second +40 mV depolarizing stimulus was given, a 50-millisecond -50 mV pre-voltage was given, and then repolarized to -50 mV for 5 seconds, and then returned to -80 mV. This voltage stimulus was applied every 15 seconds. After recording for 2 minutes, extracellular solution was given for 5 minutes of recording, and then the drug administration process began. The compound concentration started from the lowest test concentration, and each test concentration was given for 2.5 minutes. After all concentrations were given continuously, the positive control compound 3 μM Cisapride was given. At least 3 cells (n≥3) were tested for each concentration.

[0193] (3) Compound preparation: Dilute the compound stock solution with DMSO, take 10 μL of the compound stock solution and add it to 20 μL of DMSO solution, and dilute it 3 times to 6 DMSO concentrations. Take 4 μL of the compound with 6 DMSO concentrations respectively, add it to 396 μL of extracellular fluid, dilute it 100 times to 6 intermediate concentrations, then take 80 μL of the 6 intermediate concentration compounds respectively, add it to 320 μL of extracellular fluid, and dilute it 5 times to the final concentration to be tested. The highest test concentration is 40.00 μM, and there are 6 concentrations of 40.00, 13.33, 4.44, 1.48, 0.49, and 0.16 μM respectively. The DMSO content in the final test concentration does not exceed 0.2%, and this concentration of DMSO has no effect on hERG potassium channels. The compound preparation is completed by the Bravo instrument throughout the dilution process.

[0194] (4) Data analysis: The experimental data were analyzed using GraphPad Prism 5.0 software.

[0195] Table 5 hERG potassium channel effect test results of compounds (IC 50 / μM)

[0196]

[0197] The hERG test results show that the inhibitory activity of the compounds of the present invention on hERG potassium ion channels is greater than 35 μM, indicating that the potential cardiac toxicity of the compounds of the present invention is relatively low.

[0198] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitution combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the scope of the present invention.

Claims

1. A hydroxamic acid Mer / HDAC dual-target inhibitor, characterized in that: The general formula is: R 1 Selected from alkyl, alkoxyethyl, cycloalkyl, substituted cycloalkyl; R 2 Selected from H, aryl, aromatic heterocyclic group, substituted aromatic heterocyclic group.

2. The hydroxamic acid Mer / HDAC dual-target inhibitor according to claim 1, characterized in that: R 1 is selected from trans-hydroxycyclohexyl, cyclohexyl, methoxyethyl, trans-methylcyclohexyl; R 2 Selected from H, phenyl, 5-pyrimidinyl, 3-methoxy-2-pyridinyl.

3. The hydroxamic acid Mer / HDAC dual-target inhibitor according to claim 1, characterized in that: R 1 The groups are: R 2 Selected from the following groups:

4. A method for preparing the hydroxamic acid Mer / HDAC dual-target inhibitor according to claim 3, characterized in that: Its synthetic route is: The specific steps include: 1) 2,4-dichloro-5-bromopyrimidine reacts with compound II in the presence of an acid-binding agent to obtain intermediate III; 2) Intermediate III reacts with 8-((4-aminophenyl)amino)-8-oxooctanoic acid methyl ester in the presence of an acid catalyst to obtain intermediate IV; 3) Intermediate IV and compound V are subjected to Suzuki coupling reaction in the presence of a catalyst to obtain intermediate VI; 4) intermediate VI is subjected to hydrolysis reaction in the presence of a base catalyst to obtain intermediate VII; 5) intermediate VII is reacted with O-(tetrahydro-2H-pyran-2-yl)hydroxylamine in the presence of a base catalyst to obtain intermediate VIII; 6) Intermediate VIII is deprotected to obtain target compounds I-1 to I-3.

5. The preparation method according to claim 4, characterized in that: The condensing agent used in step 5) is HBTU, HATU, HOBt or TFCH; the catalyst in step 6) is trifluoroacetic acid, hydrochloric acid or sulfuric acid.

6. The hydroxamic acid Mer / HDAC dual-target inhibitor according to claim 1, characterized in that: R 1 Selected from the following groups: R 2 The group is H.

7. A preparation method according to claim 6, characterized in that: Its synthetic route is: The specific steps include: a) 2,4-dichloropyrimidine reacts with compound II in the presence of an acid-binding agent to obtain intermediate IX; b) reacting methyl 8-((4-aminophenyl)amino)-8-oxooctanoate with intermediate IX in the presence of an acid catalyst to obtain intermediate X through nucleophilic substitution reaction; c) intermediate X is subjected to a hydrolysis reaction in the presence of a base catalyst to obtain intermediate XI; d) intermediate XI is reacted with O-(tetrahydro-2H-pyran-2-yl)hydroxylamine in the presence of a base catalyst to obtain intermediate XII; e) Intermediate XII is deprotected to obtain target compounds I-4 to I-8.

8. The preparation method according to claim 7, characterized in that: The condensation agent used in step d) is HBTU, HATU, HOBt or TFCH; the catalyst in step e) is trifluoroacetic acid, hydrochloric acid or sulfuric acid.

9. Use of the hydroxamic acid Mer / HDAC dual-target inhibitor according to any one of claims 1, 2, 3 or 6 in the preparation of anti-tumor drugs.

10. The use according to claim 9, characterized in that: The anti-tumor drug is indicated for at least one of chronic myeloid leukemia, myelomonocytic leukemia, non-small cell lung cancer, colorectal cancer, liver cancer and prostate cancer.

Citation Information

Patent Citations

  • Pyrimidine compounds for the treatment of cancer

    CN104302627A

  • 2,4-diarylamine pyrimidine derivatives containing hydroxamic acid fragments and preparation and application

    CN105646371A

  • Therapuetic uses of selected pyrimidine compounds with Anti-MER tyrosine kinase activity

    WO2015157127A1

  • Novel pan-TAM inhibitors and mer / AXL dual inhibitors

    WO2017059280A1

  • Compounds with mertk activity

    WO2023235925A1